Cargando…

Knowing the Bad: Adverse Event–Informed, High-Risk, Early-Stage Non-Small Cell Lung Cancer Treatment Options

Detalles Bibliográficos
Autor principal:	Phillips, Joseph D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Thoracic Society 2022
Materias:	Editorials
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9743475/ https://www.ncbi.nlm.nih.gov/pubmed/36454168 http://dx.doi.org/10.1513/AnnalsATS.202209-756ED

Ejemplares similares

Therapy option for early-stage lung cancer in nonsurgical patients
por: Safi, Seyer, et al.
Publicado: (2022)

The more we learn, the more there is to know: the clinical management of stage I non-small cell lung cancer
por: Engelhardt, Kathryn E., et al.
Publicado: (2022)

Novel teatment options in early-stage non-small-cell lung cancer
por: van Meerbeeck, Jan P.
Publicado: (2013)

Biomarkers predictive value in early stage non-small cell lung cancer
por: Malapelle, Umberto, et al.
Publicado: (2020)

Treatments for Non-Small-Cell Lung Cancer: The Multiple Options for Precision Medicine
por: Pons-Tostivint, Elvire, et al.
Publicado: (2022)

Wedge resection—finding its place in early-stage non-small cell lung cancer?
por: Hill, Morgan A., et al.
Publicado: (2023)

If You Know Them, You Avoid Them: The Imperative Need to Improve the Narrative Regarding Perioperative Adverse Events
por: Eppler, Michael, et al.
Publicado: (2022)

Is It Time to Cross the Pillars of Evidence in Favor of Segmentectomies in Early-Stage Non-Small Cell Lung Cancer?
por: Bertolaccini, Luca, et al.
Publicado: (2023)

Pulmonary segmentectomy for early stage non-small cell lung cancer: when, for which cases and how
por: Matsuura, Natsumi, et al.
Publicado: (2023)

The Good, Bad and not so Bad of Positive Thinking and Recovery
por: Chaturvedi, Santosh K.
Publicado: (2023)

Small, Enigmatic Plasmids of the Nosocomial Pathogen, Acinetobacter baumannii: Good, Bad, Who Knows?
por: Lean, Soo Sum, et al.
Publicado: (2017)

“It wasn’t as bad as I thought it would be”: a qualitative study of early stage non-small cell lung cancer patients after treatment
por: Golden, Sara E., et al.
Publicado: (2017)

Dose matters for stereotactic body radiotherapy for early stage non-small cell lung cancer
por: Okoye, Christian C., et al.
Publicado: (2020)

Therapeutic management options for stage III non-small cell lung cancer
por: Yoon, Stephanie M, et al.
Publicado: (2017)

Stage III Non-Small-Cell Lung Cancer: An Overview of Treatment Options
por: Petrella, Francesco, et al.
Publicado: (2023)

The IP Waiver for COVID-19: Bad Policy, Bad Precedent
por: Mercurio, Bryan
Publicado: (2021)

The power of immunotherapy plus platinum–based chemotherapy for locally advanced or early stage non-small cell lung cancer
por: Hofman, Paul
Publicado: (2020)

Surgery for early-stage small cell lung cancer: is it worth it?
por: Vyfhuis, Melissa A. L., et al.
Publicado: (2019)

Thoracoscopic anatomical segmentectomy for early-stage non-small cell lung cancer: minimally invasive surgery involving various approaches
por: Kato, Hirohisa
Publicado: (2023)

Bad for the Temperance Cause
Publicado: (1880)

The Revival of Bad Methods
Publicado: (1898)

Impact of neuroimaging in the pretreatment evaluation of early stage non-small cell lung cancer
por: Wasp, Garrett T., et al.
Publicado: (2020)

Surgery for stage IV non-small cell lung cancer?
por: Puig, Carlos A., et al.
Publicado: (2020)

What we know about surgical therapy in early-stage non-small-cell lung cancer: a guide for the medical oncologist
por: Ghanem, Sassine, et al.
Publicado: (2017)

EGFR tyrosine kinase inhibitors (TKIs) for adjuvant therapy of early-stage non-small cell lung cancer (NSCLC): ready for the clinic?
por: Steuer, Conor E., et al.
Publicado: (2020)

Bad Breath
Publicado: (1860)

The good, the bad and the ugly!! - Antibiotics
por: Damle, S. G.
Publicado: (2015)

Debt: The Good. The Bad. The Ugly
por: Boz, Emine, et al.
Publicado: (2021)

Ontario’s Bad Example Continues
Publicado: (1898)

Insights into the Spectrum of Chronic Lower Respiratory Disease: Low Lung Function Is Still Bad
por: Mannino, David M.
Publicado: (2021)

Wants to Know You Know
Publicado: (1885)

Management of Immune-Related Adverse Events in Patients With Non-Small Cell Lung Cancer
por: Burke, Michael, et al.
Publicado: (2021)

Expression and prognostic relevance of MET and phospho-BAD in non-small cell lung cancer
por: Sun, Wenze, et al.
Publicado: (2013)

Three aspects of acupuncture-related adverse events: Issues around the reporting of acupuncture-related adverse events
por: Kim, Tae-Hun, et al.
Publicado: (2023)

Breaking bad news: what parents would like you to know
por: Brouwer, Marije A, et al.
Publicado: (2021)

KEYNOTE-407: an effective and safe first-line treatment option for metastatic squamous non-small cell lung cancer
por: Chen, Hao, et al.
Publicado: (2023)

Radical segmentectomy as a potential alternative surgical treatment with curative intent in early-stage non-small cell lung cancer
por: Koike, Terumoto, et al.
Publicado: (2020)

The path forward in early-stage lung cancer
por: Cuppens, Kristof, et al.
Publicado: (2022)

Tarlatamab: a potential new option for recurrent small cell lung cancer
por: Addeo, Alfredo, et al.
Publicado: (2023)

Response to “Evaluating Adverse Events in Databases”
por: Calapai, Fabrizio, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_1qhnmegu75la4i73mm3dhenqna